MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
Forums
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

New Tetrahydroisoquinoline derivatives

University of Liège (ULg), Interface Entreprises-Université, Liege
The University of Liege has discovered a new tetrahydroisoquinoline and its derivatives and their preparation exhibiting a significant affinity for SK channels, particularly at the Apamin-sensitive sites of SK channels.

Full description

The Small conductance calcium activated potassium (SK) channels underlie the prolonged post-spike afterhyperpolarization (AHP), which plays an important role in modulating the firing rate and the firing pattern of neurones.

Up to now, Apamine extrated from the venom of honeybee is said the most potent SK channel bloker. However, it can’t be used for therapeuticals treatment due to its toxicity. Deliqualinium and its derivatives present a poor therapeutic action for the treatment of CNS diseases.

The University of Liege has discovered a new tetrahydroisoquinoline and its derivatives and their preparation exhibiting a significant affinity for SK channels, particularly at the Apamin-sensitive sites of SK channels.

Development status

Preclinical

Patent information

WO 2007/107442  pending.

Type of business relationship sought

Opportunities are available,

research contract  and/ collaboration  for the test and development of the molecule

Licensing contact

Mr Julian Vultaggio
Transfer technology Advisor

Contact directly

Company details

University of Liège (ULg), Interface Entreprises-Université, Liege

The Interface Entreprises-Université is a multidisciplinary team committed to industry, which is responsible of the Liège University technology transfer (IP protection, licences, spinoff

View profile

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Therapeutic target
Central Nervous System

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
The countdown has started...
Stem Cell USA
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us